Ivesa (firmonertinib) / Allist, ArriVent 
Welcome,         Profile    Billing    Logout  
 0 Diseases   3 Trials   3 Trials   3 News 
79 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ivesa (firmonertinib) / Allist, ArriVent
ChiCTR2400085155: Prospective, Randomized Controlled Clinical Trial of the Efficacy and Safety of in the Treatment of Residual Ground-glass Nodules after Surgery for EGFR Mutation-positive Multiplicity Primary Lung Cancer

Not yet recruiting
4
300
 
Oral Furmonertinib 80mg/day; Follow-up observation
The Second Affiliated Hospital of Army Medical University.; The Second Affiliated Hospital of Army Medical University., Chongqing Technology Innovation and Application Development Key Projects, Grant/Award Number:CSTB2022TIAD-CUX0019
lung cancer
 
 
SELECT-2, NCT04401059: Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study

Recruiting
4
744
RoW
Elemene plus first or third generation EGFR-TKIs, H10960114, H20010338, First or third generation EGFR-TKIs, Gefitinib(Iressa,YiRuiKe), Erlotinib(Tarceva), Icotinib(Kaimeina), Osimertinib(Tagrisso), Almonertinib, Furmonertinib, etc.
Tian Xie, LinkDoc Technology (Beijing) Co. Ltd.
Carcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma
09/25
03/26
ChiCTR2300072027: A Multi-center, Single-arm Phase II Clinical Trial of Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Exon 21 L858R Mutation-positive Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer

Recruiting
4
35
 
Furmonertinib 80mg/day orally on a continuous dosing schedule Anlotinib 12mg/day orally from day 1 to 14 of a 21-day cycle
Sichuan Cancer Hospital; Sichuan Cancer Hospital, CSCO-ALLIST Research Fund Project of Targeted therapy for lung cancer(2021)
Lung cancer
 
 
ChiCTR2300076712: Neoadjuvent therapy of furmonertinib for locally advanced lung adenocarcinoma with EGFR mutation: a prospective single arm, multicenter clinical trial

Not yet recruiting
4
40
 
Furmonertinib
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Beijing Xisike Clinical Oncology Research Foundation
lung adenocarcinoma
 
 
ChiCTR2400080739: An exploratory multi-cohort Clinical Study of Glumetinib in the treatment of advanced non-small cell lung cancer brain metastases with MET alterations (BRAIN-MET01)

Recruiting
4
40
 
Glumetinib (300mg) will be administered orally in a 4-week treatment cycle, once a day from day 1 to day 28 of each cycle.; Glumetinib+FurmonertinibGlumetinib (300mg) will be administered orally in a 4-week treatment cycle, once a day from day 1 to day 28 of each cycle.Furmonertinib (80mg) will be administered orally in a 4-week treatment cycle, once a day from day 1 to day 28 of each cycle.
Beijing Tiantan Hospital, Capital Medical University; Beijing Tiantan Hospital, Capital Medical University, CSPC Ouyi Pharmaceutical Co., Ltd.
NSCLC
 
 
ChiCTR2500097458: Efficacy and Safety of Firmonertinib with Concurrent Radiotherapy versus Chemoradiation followed by Firmonertinib consolidation therapy in patients with unresectable or inoperable EGFR-mutant stage II-III NSCLC: a multicenter, randomized, open-label, Phase II trial

Not yet recruiting
4
80
 
Firmonertinib with Concurrent Radiotherapy, followed by Firmonertinib Consolidation Therapy; Chemoradiation, followed by Firmonertinib Consolidation Therapy; Firmonertinib with Concurrent Radiotherapy, followed by Firmonertinib Consolidation Therapy
Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital Institute); Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital Institute), Shanghai Allist Pharmaceuticals Co., Ltd
NSCLC
 
 
ChiCTR2500099395: 160mg furmonertinib for the first-line treatment of EGFR-sensitive mutations NSCLC with BM/LM : a single-arm, prospective clinical study

Not yet recruiting
4
30
 
furmonertinib 160 mg orally once daily on an empty stomach.
The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University, Funding provided by the researcher
NSCLC
 
 
FURLONG, NCT03787992: Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Active, not recruiting
3
358
RoW
Alflutinib Mesylate (AST2818) 80mg//40 mg+ placebo, Placebo Gefitinib 250 mg, Gefitinib 250 mg, Placebo AST2818 80mg//40 mg
Allist Pharmaceuticals, Inc.
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
09/21
03/26
2022-002006-24: Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Estudio para comparar furmonertinib con quimioterapia basada en platino para pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico

Not yet recruiting
3
375
Europe
Furmonertinib, AST2818, Tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion, Pemetrexed Hospira 500 mg powder for concentrate for solution for infusion, Pemetrexed Accord 500 mg powder for concentrate for solution for infusion., Carboplatin Hikma 10 mg/mL concentrate for solution for infusion, Carboplatin Bendalis 10 mg/ml Concentrate for solution for infusion, Carboplatin Fresenius Kabi 10 mg/ml, concentrate for solution for infusion, Cisplatin Hikma 1mg/ml concentrate for solution for infusion, Cisplatin Accord 1 mg/ml concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml concentrate for solution for infusion
ArriVent BioPharma, Inc., ArriVent BioPharma, Inc., Shanghai Allist Pharmaceuticals Co., Ltd.
Treatment of Patients with Previously Untreated, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations Tratamiento de pacientes con cáncer de pulmón no microcítico (CPNM) no epidermoide sin tratamiento previo, localmente avanzado o metastásico con mutaciones de inserción en el exón 20 del receptor del factor de crecimiento epidérmico (RFCE), Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico, Diseases [C] - Cancer [C04]
 
 
FORWARD, NCT04853342: To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Recruiting
3
318
RoW
Drug: Furmonertinib 80 mg, Furmonertinib 80 mg placebo
Allist Pharmaceuticals, Inc.
Non-small Cell Lung Carcinoma
01/26
01/30
NCT06674343: Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

Recruiting
3
144
RoW
Furmonertinib
Peking Union Medical College Hospital
Advanced or Metastatic Non-small Cell Lung Cancer
12/26
12/28
FURVENT, NCT05607550 / 2022-002006-24: Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations

Recruiting
3
375
Europe, Canada, Japan, US, RoW
furmonertinib 240 mg oral, daily, AST2818, furmonertinib 160 mg oral, daily, platinum-based chemotherapy
ArriVent BioPharma, Inc., Allist Pharmaceuticals, Inc.
Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
08/25
02/28
NCT05209256: Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

Not yet recruiting
2/3
90
NA
Chemotherapy, pemetrexed, Pulaile, Alflutinib plus chemotherapy, AST2818
The First Affiliated Hospital of Henan University of Science and Technology
NSCLC
01/24
01/25
TERMGGO, NCT04982900: Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities

Recruiting
2
138
RoW
furmonertinib, AST2818, Placebo
Ruijin Hospital, Fujian Medical University Union Hospital, First Affiliated Hospital of Zhejiang University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Tang-Du Hospital, The First Affiliated Hospital of Nanchang University
Multiple Primary Lung Cancers
08/22
08/22
NCT06315686: The Dynamic Monitoring of Cerebrospinal Fluid ctDNA

Recruiting
2
20
RoW
pemetrexed, Furmonertinib
Jiangsu Province Nanjing Brain Hospital
NSCLC
07/24
12/24
PIKACHU, NCT04322890: Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Recruiting
2
6000
RoW
Osimertinib, Erlotinib, Gefitinib, Furmonertinib, Almonertinib etc., Alectinib 150 MG, Lorlatinib, Alectinib, Brigatinib, Ceritinib etc., Crizotinib 250 MG, Entrectinib, Savolitinib, Crizotinib., Crizotinib, Chemotherapy, Pemetrexed, Cisplatin, Pralsetinib etc.
Hunan Province Tumor Hospital
Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROS1 Gene Mutation, MET Gene Mutation
12/26
12/27
NCT04965831: Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)

Not yet recruiting
2
40
NA
Furmonertinib, AST2818
Tianjin Medical University Cancer Institute and Hospital, Allist Pharmaceuticals, Inc.
Lung Adenocarcinoma
03/23
05/26
NCT05430802: Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE)

Recruiting
2
40
RoW
Furmonertinib+cisplating/pemetrexed
Tang-Du Hospital
Non-small Cell Lung Cancer
03/23
03/26
iFORCE, NCT05465343: Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Single-center, Open-label, Phase II Trial（）

Recruiting
2
36
RoW
Furmonertinib
Peking Union Medical College
Furmonertinib, EGFR-mutation, NSCLC, Brain Metastases
06/23
06/23
LungMate-012, NCT05503667: Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Recruiting
2
96
RoW
Furmonertinib, Ivesa, Bevacizumab, Avastin
Shanghai Pulmonary Hospital, Shanghai, China
Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation
10/23
12/28
FOCUS-A, NCT04895930: Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Recruiting
2
40
RoW
Furmonertinib, AST2818, Anlotinib
Shanghai Chest Hospital, Allist Pharmaceuticals, Inc.
Non-Small-Cell Lung Cancer
11/23
11/23
NCT05255406: Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

Recruiting
2
62
RoW
Furmonertinib (160mg), AST2818
Fudan University, Allist Pharmaceuticals, Inc.
Non-Small-Cell Lung Cancer
12/23
12/24
ChiCTR2200057048: A multicenter, open-label, prospective study: Efficacy and safety of double dose of Furmonertinib in patients with initial EGFR-mutation-positive brain metastases NSCLC or EGFR-TKI progression after treatment and EGFR-T790M positive brain metastases NSCLC

Not yet recruiting
2
60
 
Furmonertinib 160mg
West China Hospital of Sichuan University; West China Hospital of Sichuan University, Shanghai Allist Pharmaceuticals Co., Ltd
NSCLC with T790M+ brain metastases that progressed after first- and second-generation TKI treatment, and T790M+ brain metastases after first- and second-generation TKI treatment
 
 
NCT05548348: First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

Recruiting
2
30
RoW
Furmonertinib 160 mg, Q.D., AST2818 160 mg, Q.D.
Chongqing University Cancer Hospital, Army Specialty Medical Center, The Second Affilicated Hospital of Chongqing Medical University
Non-small Cell Lung Cancer, EGFR G719X, EGFR L861Q, EGFR S768I
12/23
10/25
NCT06192849: To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Recruiting
2
20
RoW
Furmonertinib
Juan LI, MD
Non Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation
12/26
01/27
NCT06339242: A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis

Recruiting
2
30
RoW
Furmonertinib, Furmonertinib Mesylate
Jiangsu Province Nanjing Brain Hospital
NSCLC
07/25
01/26
GASTO-1079, NCT04970693: A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression

Recruiting
2
64
RoW
Furmonertinib, Radiotherapy
Sun Yat-sen University
Non-small Cell Lung Cancer, Oligoprogressive
01/24
05/24
NCT06185400: RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Not yet recruiting
2
108
NA
Disitamab Vedotin, RC48, third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib), pyrotinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, ERBB2 Gene Duplication, Disitamab Vedotin
07/25
12/26
NCT05466149: Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

Active, not recruiting
2
100
RoW
Furmonertinib, AST2818
Allist Pharmaceuticals, Inc.
NSCLC
09/25
12/26
NCT06319950: High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Not yet recruiting
2
255
NA
Furmonertinib, AST2818, alflutinib, Osimertinib, AZ9291
Taizhou Hospital
Lung Cancer, Nonsmall Cell
12/26
12/26
NCT06394674: High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

Recruiting
2
84
RoW
Furmonertinib, AST2818
Changhai Hospital, The General Hospital of Eastern Theater Command, Shanghai Chest Hospital, Fujian Provincial Hospital, Shanghai Changzheng Hospital, First Affiliated Hospital Bengbu Medical College, The First People's Hospital of Changzhou, Second Affiliated Hospital of Wannan Medical College
Non-Small Cell Lung Cancer
06/25
09/26
NCT06452433: Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Not yet recruiting
2
91
NA
gumarontinib, SCC244, third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib), third-generation EGFR-TKI
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-small Cell Lung Cancer
12/27
02/28
LungBrain001, NCT06483672: Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases

Not yet recruiting
2
27
NA
Furmonertinib, AST2818, Anlotinib, No other intervention names
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Adenocarcinoma of Lung Metastatic to Brain
12/25
12/27
FORCE, NCT05379803: High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

Recruiting
2
40
RoW
Furmonertinib, AST2818
Hunan Province Tumor Hospital
Non-Small Cell Lung Cancer
12/24
03/25
NCT05987826: Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

Not yet recruiting
2
40
NA
Furmonertinib, Furmonertinib(AST2818)
Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Shanghai Minhang Central Hospital, Shanghai Zhongshan Hospital Qingpu Branch, Ningbo No. 1 Hospital
Non-Small Cell Lung Cancer
08/24
12/25
ChiCTR2200060151: Furonertinib mesylate with Icotinib as first line treatment in locally advanced or metastatic non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutation positive: a single-arm single-center phase II study

Recruiting
2
40
 
Furmonertinib+Icotinib
Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University, Xisike-Allist Lung Cancer Target Therapy Research Foundation; Shanghai Allist Pharmaceuticals Co., Ltd.; Betta Pharmaceuticals Co., Ltd.
Lung cancer
 
 
Better Brain, NCT06728865: Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study

Recruiting
2
70
RoW
The treatment regimen is Furmonertinib combined with Bevacizumab.
Li-kun Chen
Non-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer, Brain Metastases, Leptomeningeal Metastases, Intracranial Tumor Progression
02/28
02/28
NCT06537297: Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

Not yet recruiting
2
30
RoW
Intrathecal Pemetrexed and high-dose Furmonertinib plus bevacizumab, intrathecal pemetrexed, high-dose furmonertinib, bevacizumab
Hunan Province Tumor Hospital
Non-small Cell Lung Cancer
08/25
04/26
NCT05847764: Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Not yet recruiting
2
95
RoW
RC48+Tislelizumab+carboplatin, RC48+Furmonertinib, 1L, RC48+Furmonertinib, 2L+
Sun Yat-sen University
Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, RC48, Disitamab Vedotin
10/24
05/25
NCT06585644: A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC

Not yet recruiting
2
44
NA
Shanghai Pulmonary Hospital, Shanghai, China
Lung Cancer (NSCLC)
11/25
06/30
NCT06652048: High-dose Furmonertinib or Combined with Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

Not yet recruiting
2
60
NA
Furmonertinib 160mg QD, Furmonertinib 240mg QD, Furmonertinib 160mg QD plus Chemotherapy
Jialei Wang
Non-Small Cell Lung Cancer
12/26
12/27
ATHEM, NCT05165355: Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma

Recruiting
2
90
RoW
Furmonertinib
Tongji University
NSCLC, EGF-R Positive Non-Small Cell Lung Cancer
11/24
02/25
NCT06812871: High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Recruiting
2
30
RoW
furmonertinib, bevacizumab, pemetrexed
Sun Yat-sen University
Non-small Cell Lung Cancer Metastatic
12/25
04/26
NCT06668103: A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

Recruiting
2
54
RoW
ABSK043 in combination with Firmonertinib
Abbisko Therapeutics Co, Ltd
Non-Small Cell Lung Cancer With EGFR Mutation
12/27
06/28
ChiCTR2100053119: A multicenter, open label, single arm study: furmonertinib as neoadjuvant therapy for resectable stage IIIA EGFR mutant lung adenocarcinoma

Recruiting
2
40
 
Furmonertinib
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Hospital; Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Hospital, Shanghai Allis Pharmaceuticals Co.,Ltd.
Non-small cell lung cancer
 
 
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Recruiting
2
280
RoW
Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd.
Non-small Cell Lung Cancer
02/25
02/28
NCT06890182: Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC

Not yet recruiting
2
31
NA
Firmonertinib combined with Carboplatin/Cisplatin and Pemetrexed
Tianjin Medical University Cancer Institute and Hospital
Non-small Cell Lung Cancer
12/26
12/27
NCT06861218: Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases

Not yet recruiting
2
42
RoW
pemetrexed, vometinib
Zhejiang Cancer Hospital
Leptomeningeal Metastases
05/28
12/28
NCT05813522: Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC

Enrolling by invitation
2
30
RoW
Furmonertinib Mesilate Tablets, AST2818
First Affiliated Hospital of Zhejiang University
Non Small Cell Lung Cancer
04/25
08/25
ChiCTR2200062769: A Clinical Study of Furmonertinib Combined with Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIA EGFRm NSCLC

Not yet recruiting
2
42
 
Furmonertinib+ Pemetrexed + Carboplatin
Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, Shanghai Allist Pharmaceuticals Co, Ltd.
Non small cell lung cancer
 
 
ChiCTR2300076542: An IIT, open-label, multi-arm, prospective clinical study to investigate the efficacy and safety of toripalimab combined with furmonertinib in non-small cell lung cancer patients with EGFR sensitive mutations and PD-L1 >= 1% of first-line treatment

Not yet recruiting
2
36
 
Cohort 1: Furmonertinib 80mg orally once a day + Toripalimab 240mg intravenously every 3 weeks.Cohort 2: Induction therapy with 80mg of Furmonertinib in first 8 weeks, sequential oral administration of Furmonertinib 80mg once a day + Toripalimab 240mg intravenously every 3 weeks.
West China Hospital of Sichuan University; West China Hospital of Sichuan University, Partly funded by Shanghai Junshi Biosciences Co.,Ltd., and partly self-funded
non-small-cell lung cancer
 
 
ChiCTR2200063595: A clinical study to evaluate the efficacy and safety of Furmonertinib combined with bevacizumab or Furmonertinib monotherapy in patients with brain metastases from non-squamous non-small cell lung cancer

Recruiting
2
40
 
Furmonertinib ;Furmonertinib combined with bevacizumab
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Cancer Hospital）; The First Affiliated Hospital of University of Science and Technology of China, Shanghai Allist Pharmaceuticals Co., Ltd.
Non small cell lung cancer
 
 
ChiCTR2300071395: The efficacy and safety of Furmonertinib in advanced EGFR mutation-positive NSCLC patients with brain metastases based on real-time dynamic monitoring of peripheral blood and CSF

Not yet recruiting
2
120
 
Furmonertinib 160mg, po, qd ;Furmonertinib 80 mg, po, qd ;Furmonertinib 160 mg, po, qd ;Furmonertinib 160 mg, po, qd combined with intrathecal injection MTX or MTA
Beijing Tiantan Hospital, Capital Medical University; Beijing Tiantan Hospital, Capital Medical University, National Natural Science Foundation of China(NO.81974361); Beijing Xisike Clinical Oncology Research foundation(Y-2021AST/zd-0127)
Lung Cancer
 
 
NCT05445310: Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer

Recruiting
2
114
RoW
Furmonertinib
Peking Union Medical College Hospital
Non-small Cell Lung Cancer
07/26
07/26
ChiCTR2400084196: High-dose furmonertinib in combination with chemotherapy for the first-line treatment of treatment of EGFR mutant NSCLC with CNS metastasis : an open-label, single-arm study

Not yet recruiting
2
25
 
Furmonertinib 160mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed (500 mg/m2) maintenance every 3 weeks.
Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital, self-raised
Lung cancer CNS metastases
 
 
PURPOSE Trial, ChiCTR2100053021: Precise neoadjuvant therapy for locally advanced non-small cell lung cancer: a prospective, observational, umbrella trial

Not yet recruiting
2
156
 
Almonertinib ;Furmonertinib ;Osimertinib ;Ensartinib/Savolitinib/Pralsetinib/Pyrotinib ;Camrelizumab+chemotherapy ;Chemotherapy
Shanghai Chest Hospital; Shanghai Chest Hospital, Self-raised
Locally advanced non-small cell lung cancer
 
 
160mg as first line in locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR classical mutations, ChiCTR2400086161: The efficacy and safety of furmonertinib , a prospective, single-arm, multicenter clinical study

Not yet recruiting
2
144
 
Furmonertinib 160mg, PO, QD
Peking Union Medical College Hospital; Peking Union Medical College Hospital, ALLIST
Locally advanced or metastatic non-small cell lung cancer with EGFR classical mutations
 
 
ChiCTR2400088570: A Phase II Clinical Study Evaluating the Efficacy and Safety of Adjuvant Furmonertinib for Patients With EGFR-Mutated Stage IA Non-Small Cell Lung Cancer After Non-Radical Therapy

Not yet recruiting
2
88
 
Furmonertinib; Furmonertinib
Shanghai Chest Hospital; Shanghai Chest Hospital, Self-raised
EGFR-mutant stage IA non-small cell lung cancer after non-radical treatment
 
 
NCT05079022: ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

Not yet recruiting
1/2
50
RoW
Furmonertinib, AST2818, AST5902
Peking University People's Hospital, Beijing CSCO-Allist Cancer Research Foundation, Shanghai Allist Pharmaceutical Technology Co., Ltd., Guangzhou Burning Rock Medical Examination Institute Co., Ltd.
Adenocarcinoma of Lung
03/23
09/24
NCT05821933: RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

Recruiting
1/2
106
RoW
RC108, Furmonertinib, Toripalimab
RemeGen Co., Ltd.
NSCLC
09/25
09/26
NCT05994131: IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

Recruiting
1/2
110
RoW
IN10018, BI 853520, Furmonertinib
InxMed (Shanghai) Co., Ltd.
NSCLC
07/26
07/26
FAVOUR, NCT04858958: Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation

Active, not recruiting
1
30
RoW
Furmonertinib 160mg, Furmonertinib 240mg
Allist Pharmaceuticals, Inc.
NSCLC
12/24
08/25
ChiCTR2200064008: Efficacy and Safety of Furmonertinib in Locally Advanced and Metastatic Non-Small-Cell Lung Cancer Harbouring HER2 Exon 20 Insertion: A Single-Center, Open-Label, Phase Ib Trial

Not yet recruiting
1
30
 
Furmonertinib 240mg, po, qd ;Furmonertinib 240mg, po, qd
Chinese PLA General Hospital; Chinese PLA General Hospital, Allist Pharmaceuticals, Inc.
non-small cell lung cancer (NSCLC)
 
 
NCT06868732: Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC

Not yet recruiting
1
288
NA
JSKN016, Carboplatin, Carboplatin Injection, Furmonertinib Mesylate, Furmonertinib Mesylate Tablets, Ivonescimab, Ivonescimab Injection, Docetaxel, Docetaxel injection, Tislelizumab, Tislelizumab Injection, Pembrolizumab, Pembrolizumab Injection
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Non-small Cell Lung Cancer
06/28
12/28
ChiCTR2200060897: High Dose FurmOnertinib in treatment naive advanced non-small cell lung Cancer patients Harbouring EGFR Exon 21 L858R mutation:a prospective, multicenter, single arm, open label, phase Ib study

Not yet recruiting
1
25
 
Furmonertinib 160mg Oral QD
JiangSu Cancer Hospital ; JiangSu Cancer Hospital, Shanghai Allist Pharmaceuticals Co., Ltd.
Non Small Cell lung cancer
 
 
FURMO-002, NCT05364073: Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Active, not recruiting
1
170
Europe, Canada, Japan, US, RoW
Furmonertinib, AST2818
ArriVent BioPharma, Inc.
Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations, EGFR Exon 20 Mutations, EGFR Uncommon Mutations, Including G719X and S768I
09/25
09/25
ChiCTR2400088658: Phase I clinical study of induction radiotherapy followed by neoadjuvant chemotherapy combined with Furmonertinib and adjuvant therapy with single-agent Furmonertinib for EGFR mutated resectable non-small cell lung cancer

Not yet recruiting
1
60
 
8Gy x Three times radiotherapy of peripheral primary focus 4Gy x Three times radiotherapy of central primary focus ; Pemetrexed 500mg/m2+ carboplatin AUC=5; D1, D22; Vometinib 80mg/ time orally, once a day, chemotherapy was started simultaneously, D1 ~ D49/56/63, until 1 week before surgery. Starting from 4 to 6 weeks after surgery, and no later than 8 weeks after surgery, continue to consolidate targeted therapy, orally once a day for 2 years
Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, Self-raised
resectable stage IIA-IIIA non-small cell lung cancer
 
 
ChiCTR2300077828: Double-Dose Versus Conventional-Dose Furmonertinib for the First-Line Treatment of EGFR-Mutated NSCLC with Malignant Pleural Effusion: An Open-Label, Randomized Controlled, Multicenter, Phase Ib Trial

Not yet recruiting
1
50
 
Furmonertinib 80mg QD; Furmonertinib 160mg QD
The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University, Shanghai Allist Pharmaceuticals Co., Ltd.
Non-small cell lung cancer
 
 
NCT06613633: Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

Completed
N/A
4000
RoW
third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)
Fudan University, Shanghai Chest Hospital, Wuhan TongJi Hospital
Third-generation TKI, NSCLC (Advanced Non-small Cell Lung Cancer)
08/24
09/24
NCT06352502: An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis

Recruiting
N/A
30
RoW
Furmonertinib, AST2818
Tang-Du Hospital
EGF-R Positive Non-Small Cell Lung Cancer, CNS Metastases
09/24
09/24
NCT06604689: AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases

Recruiting
N/A
800
RoW
third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
Fudan University
NSCLC (Advanced Non-small Cell Lung Cancer), Brain Metastasases
04/25
10/25
ChiCTR2200066546: High-dose Furmonertinib in first-line treatment of patients with EGFR classically mutated advanced NSCLC: a multicenter, open-label, single-arm, clinical study

Recruiting
N/A
15
 
Furmonertinib 160mg
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Shanghai Allist Pharmaceutical Technology Co. LTD
Non-small cell lung cancer
 
 
NCT06643000: Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Recruiting
N/A
60
RoW
furmonertinib, bevacizumab, pemetrexed
Henan Cancer Hospital
Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation
03/25
05/25
NCT06926803: A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With Leptomeningeal Metastases

Active, not recruiting
N/A
500
RoW
Qiming Wang
Lung Cancer (NSCLC), Leptomeningeal Cancer
06/25
08/25
A clinical study of Furmonertinib in patients with resectable multiple primary NSCLC after one-side R0 resection, ChiCTR2300068802: A multicenter, single-arm clinical study to evaluate the efficacy and safety of Furmonertinib treatment in patients with resectable multiple primary NSCLC after one-side R0 resection

Not yet recruiting
N/A
20
 
Furmonertinib
The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University, Shanghai Allist Pharmaceuticals Co., Ltd.
Non-small cell lung cancer
 
 
ChiCTR2300072092: A single-center,real-world study to evaluate the efficacy and safety of Furmonertinib-Mesylate of 240mg/ day in the treatment of advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor gene mutation and Leptomeningeal metastasis

Recruiting
N/A
50
 
Furmonertinib oral 240mg/d
Henan Cancer Hospital; Henan Cancer Hospital, self-financing
advanced non-small cell lung cancer with epidermal growth factor receptor gene mutation and leptomeningeal metastasis
 
 
NCT06117644: The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Not yet recruiting
N/A
30
NA
Furmonertinib
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Non Small Cell Lung Cancer, EGFR Gene Mutation, Non Small Cell Lung Cancer Stage IIIA, Non-small Cell Lung Cancer Stage IV
11/25
10/26
ChiCTR2500096734: A real-world study of vormetinib in patients with EGFR mutation-positive NSCLC who relapsed after adjuvant therapy with the first generation EGFR-TKI after radical surgery

Recruiting
N/A
50
 
Furmonertinib
The Forthe Hospital of Hebei Medical University; The Forthe Hospital of Hebei Medical University, Funding provided by the researcher
EGFR Mutation-Positive NSCLC Patients with Recurrence After Adjuvant Therapy with First-Generation EGFR-TKIs Following Radical Resection
 
 
ChiCTR2400088200: A prospective, single-arm clinical study of furmonertinib combined with chemotherapy in the first-line treatment of patients with EGFR mutant locally advanced or metastatic non-small cell lung cancer

Not yet recruiting
N/A
51
 
furmonertinib combined with chemotherapy
hunan cancer hospital; hunan cancer hospital, National Natural Science Foundation of China;Hunan Provincial Health Commission;Natural Science Foundation Project of Changsha Science and Technology Bureau;Guangdong Clinical Trial Association/China Thoracic Tumour Research Collaboration Group and Guangdon;Shanghai Allist Pharmaceuticals Co., Ltd.
EGFR mutation positive locally advanced or metastatic non-small cell lung cancer
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ivesa (firmonertinib) / Allist, ArriVent
ChiCTR2400085155: Prospective, Randomized Controlled Clinical Trial of the Efficacy and Safety of in the Treatment of Residual Ground-glass Nodules after Surgery for EGFR Mutation-positive Multiplicity Primary Lung Cancer

Not yet recruiting
4
300
 
Oral Furmonertinib 80mg/day; Follow-up observation
The Second Affiliated Hospital of Army Medical University.; The Second Affiliated Hospital of Army Medical University., Chongqing Technology Innovation and Application Development Key Projects, Grant/Award Number:CSTB2022TIAD-CUX0019
lung cancer
 
 
SELECT-2, NCT04401059: Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study

Recruiting
4
744
RoW
Elemene plus first or third generation EGFR-TKIs, H10960114, H20010338, First or third generation EGFR-TKIs, Gefitinib(Iressa,YiRuiKe), Erlotinib(Tarceva), Icotinib(Kaimeina), Osimertinib(Tagrisso), Almonertinib, Furmonertinib, etc.
Tian Xie, LinkDoc Technology (Beijing) Co. Ltd.
Carcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma
09/25
03/26
ChiCTR2300072027: A Multi-center, Single-arm Phase II Clinical Trial of Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Exon 21 L858R Mutation-positive Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer

Recruiting
4
35
 
Furmonertinib 80mg/day orally on a continuous dosing schedule Anlotinib 12mg/day orally from day 1 to 14 of a 21-day cycle
Sichuan Cancer Hospital; Sichuan Cancer Hospital, CSCO-ALLIST Research Fund Project of Targeted therapy for lung cancer(2021)
Lung cancer
 
 
ChiCTR2300076712: Neoadjuvent therapy of furmonertinib for locally advanced lung adenocarcinoma with EGFR mutation: a prospective single arm, multicenter clinical trial

Not yet recruiting
4
40
 
Furmonertinib
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Beijing Xisike Clinical Oncology Research Foundation
lung adenocarcinoma
 
 
ChiCTR2400080739: An exploratory multi-cohort Clinical Study of Glumetinib in the treatment of advanced non-small cell lung cancer brain metastases with MET alterations (BRAIN-MET01)

Recruiting
4
40
 
Glumetinib (300mg) will be administered orally in a 4-week treatment cycle, once a day from day 1 to day 28 of each cycle.; Glumetinib+FurmonertinibGlumetinib (300mg) will be administered orally in a 4-week treatment cycle, once a day from day 1 to day 28 of each cycle.Furmonertinib (80mg) will be administered orally in a 4-week treatment cycle, once a day from day 1 to day 28 of each cycle.
Beijing Tiantan Hospital, Capital Medical University; Beijing Tiantan Hospital, Capital Medical University, CSPC Ouyi Pharmaceutical Co., Ltd.
NSCLC
 
 
ChiCTR2500097458: Efficacy and Safety of Firmonertinib with Concurrent Radiotherapy versus Chemoradiation followed by Firmonertinib consolidation therapy in patients with unresectable or inoperable EGFR-mutant stage II-III NSCLC: a multicenter, randomized, open-label, Phase II trial

Not yet recruiting
4
80
 
Firmonertinib with Concurrent Radiotherapy, followed by Firmonertinib Consolidation Therapy; Chemoradiation, followed by Firmonertinib Consolidation Therapy; Firmonertinib with Concurrent Radiotherapy, followed by Firmonertinib Consolidation Therapy
Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital Institute); Shandong First Medical University and Shandong Academy of Medical Sciences (Shandong Cancer Hospital Institute), Shanghai Allist Pharmaceuticals Co., Ltd
NSCLC
 
 
ChiCTR2500099395: 160mg furmonertinib for the first-line treatment of EGFR-sensitive mutations NSCLC with BM/LM : a single-arm, prospective clinical study

Not yet recruiting
4
30
 
furmonertinib 160 mg orally once daily on an empty stomach.
The Fourth Hospital of Hebei Medical University; The Fourth Hospital of Hebei Medical University, Funding provided by the researcher
NSCLC
 
 
FURLONG, NCT03787992: Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Active, not recruiting
3
358
RoW
Alflutinib Mesylate (AST2818) 80mg//40 mg+ placebo, Placebo Gefitinib 250 mg, Gefitinib 250 mg, Placebo AST2818 80mg//40 mg
Allist Pharmaceuticals, Inc.
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
09/21
03/26
2022-002006-24: Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Estudio para comparar furmonertinib con quimioterapia basada en platino para pacientes con cáncer de pulmón no microcítico localmente avanzado o metastásico

Not yet recruiting
3
375
Europe
Furmonertinib, AST2818, Tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Pemetrexed Fresenius Kabi 500 mg powder for concentrate for solution for infusion, Pemetrexed Hospira 500 mg powder for concentrate for solution for infusion, Pemetrexed Accord 500 mg powder for concentrate for solution for infusion., Carboplatin Hikma 10 mg/mL concentrate for solution for infusion, Carboplatin Bendalis 10 mg/ml Concentrate for solution for infusion, Carboplatin Fresenius Kabi 10 mg/ml, concentrate for solution for infusion, Cisplatin Hikma 1mg/ml concentrate for solution for infusion, Cisplatin Accord 1 mg/ml concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml concentrate for solution for infusion
ArriVent BioPharma, Inc., ArriVent BioPharma, Inc., Shanghai Allist Pharmaceuticals Co., Ltd.
Treatment of Patients with Previously Untreated, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations Tratamiento de pacientes con cáncer de pulmón no microcítico (CPNM) no epidermoide sin tratamiento previo, localmente avanzado o metastásico con mutaciones de inserción en el exón 20 del receptor del factor de crecimiento epidérmico (RFCE), Non-Small Cell Lung Cancer Cáncer de pulmón no microcítico, Diseases [C] - Cancer [C04]
 
 
FORWARD, NCT04853342: To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Recruiting
3
318
RoW
Drug: Furmonertinib 80 mg, Furmonertinib 80 mg placebo
Allist Pharmaceuticals, Inc.
Non-small Cell Lung Carcinoma
01/26
01/30
NCT06674343: Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

Recruiting
3
144
RoW
Furmonertinib
Peking Union Medical College Hospital
Advanced or Metastatic Non-small Cell Lung Cancer
12/26
12/28
FURVENT, NCT05607550 / 2022-002006-24: Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations

Recruiting
3
375
Europe, Canada, Japan, US, RoW
furmonertinib 240 mg oral, daily, AST2818, furmonertinib 160 mg oral, daily, platinum-based chemotherapy
ArriVent BioPharma, Inc., Allist Pharmaceuticals, Inc.
Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations
08/25
02/28
NCT05209256: Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

Not yet recruiting
2/3
90
NA
Chemotherapy, pemetrexed, Pulaile, Alflutinib plus chemotherapy, AST2818
The First Affiliated Hospital of Henan University of Science and Technology
NSCLC
01/24
01/25
TERMGGO, NCT04982900: Treatment of EGFR-TKI for Residual Lesions of Multiple Synchronous Ground-glass Opacities

Recruiting
2
138
RoW
furmonertinib, AST2818, Placebo
Ruijin Hospital, Fujian Medical University Union Hospital, First Affiliated Hospital of Zhejiang University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Tang-Du Hospital, The First Affiliated Hospital of Nanchang University
Multiple Primary Lung Cancers
08/22
08/22
NCT06315686: The Dynamic Monitoring of Cerebrospinal Fluid ctDNA

Recruiting
2
20
RoW
pemetrexed, Furmonertinib
Jiangsu Province Nanjing Brain Hospital
NSCLC
07/24
12/24
PIKACHU, NCT04322890: Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Recruiting
2
6000
RoW
Osimertinib, Erlotinib, Gefitinib, Furmonertinib, Almonertinib etc., Alectinib 150 MG, Lorlatinib, Alectinib, Brigatinib, Ceritinib etc., Crizotinib 250 MG, Entrectinib, Savolitinib, Crizotinib., Crizotinib, Chemotherapy, Pemetrexed, Cisplatin, Pralsetinib etc.
Hunan Province Tumor Hospital
Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROS1 Gene Mutation, MET Gene Mutation
12/26
12/27
NCT04965831: Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)

Not yet recruiting
2
40
NA
Furmonertinib, AST2818
Tianjin Medical University Cancer Institute and Hospital, Allist Pharmaceuticals, Inc.
Lung Adenocarcinoma
03/23
05/26
NCT05430802: Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIIA-IIIB Resectable NSCLC (FORESEE)

Recruiting
2
40
RoW
Furmonertinib+cisplating/pemetrexed
Tang-Du Hospital
Non-small Cell Lung Cancer
03/23
03/26
iFORCE, NCT05465343: Efficacy and Safety of Furmonertinib in Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases: A Single-center, Open-label, Phase II Trial（）

Recruiting
2
36
RoW
Furmonertinib
Peking Union Medical College
Furmonertinib, EGFR-mutation, NSCLC, Brain Metastases
06/23
06/23
LungMate-012, NCT05503667: Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma

Recruiting
2
96
RoW
Furmonertinib, Ivesa, Bevacizumab, Avastin
Shanghai Pulmonary Hospital, Shanghai, China
Lung Adenocarcinoma Stage III, Lung Adenocarcinoma Stage IV, EGFR Gene Mutation
10/23
12/28
FOCUS-A, NCT04895930: Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Recruiting
2
40
RoW
Furmonertinib, AST2818, Anlotinib
Shanghai Chest Hospital, Allist Pharmaceuticals, Inc.
Non-Small-Cell Lung Cancer
11/23
11/23
NCT05255406: Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)

Recruiting
2
62
RoW
Furmonertinib (160mg), AST2818
Fudan University, Allist Pharmaceuticals, Inc.
Non-Small-Cell Lung Cancer
12/23
12/24
ChiCTR2200057048: A multicenter, open-label, prospective study: Efficacy and safety of double dose of Furmonertinib in patients with initial EGFR-mutation-positive brain metastases NSCLC or EGFR-TKI progression after treatment and EGFR-T790M positive brain metastases NSCLC

Not yet recruiting
2
60
 
Furmonertinib 160mg
West China Hospital of Sichuan University; West China Hospital of Sichuan University, Shanghai Allist Pharmaceuticals Co., Ltd
NSCLC with T790M+ brain metastases that progressed after first- and second-generation TKI treatment, and T790M+ brain metastases after first- and second-generation TKI treatment
 
 
NCT05548348: First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation

Recruiting
2
30
RoW
Furmonertinib 160 mg, Q.D., AST2818 160 mg, Q.D.
Chongqing University Cancer Hospital, Army Specialty Medical Center, The Second Affilicated Hospital of Chongqing Medical University
Non-small Cell Lung Cancer, EGFR G719X, EGFR L861Q, EGFR S768I
12/23
10/25
NCT06192849: To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Recruiting
2
20
RoW
Furmonertinib
Juan LI, MD
Non Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation
12/26
01/27
NCT06339242: A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis

Recruiting
2
30
RoW
Furmonertinib, Furmonertinib Mesylate
Jiangsu Province Nanjing Brain Hospital
NSCLC
07/25
01/26
GASTO-1079, NCT04970693: A Study of Furmonertinib Combined With Radiotherapy for Non-small Cell Lung Cancer With Oligoprogression

Recruiting
2
64
RoW
Furmonertinib, Radiotherapy
Sun Yat-sen University
Non-small Cell Lung Cancer, Oligoprogressive
01/24
05/24
NCT06185400: RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Not yet recruiting
2
108
NA
Disitamab Vedotin, RC48, third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib), pyrotinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, ERBB2 Gene Duplication, Disitamab Vedotin
07/25
12/26
NCT05466149: Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

Active, not recruiting
2
100
RoW
Furmonertinib, AST2818
Allist Pharmaceuticals, Inc.
NSCLC
09/25
12/26
NCT06319950: High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Not yet recruiting
2
255
NA
Furmonertinib, AST2818, alflutinib, Osimertinib, AZ9291
Taizhou Hospital
Lung Cancer, Nonsmall Cell
12/26
12/26
NCT06394674: High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

Recruiting
2
84
RoW
Furmonertinib, AST2818
Changhai Hospital, The General Hospital of Eastern Theater Command, Shanghai Chest Hospital, Fujian Provincial Hospital, Shanghai Changzheng Hospital, First Affiliated Hospital Bengbu Medical College, The First People's Hospital of Changzhou, Second Affiliated Hospital of Wannan Medical College
Non-Small Cell Lung Cancer
06/25
09/26
NCT06452433: Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Not yet recruiting
2
91
NA
gumarontinib, SCC244, third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib), third-generation EGFR-TKI
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-small Cell Lung Cancer
12/27
02/28
LungBrain001, NCT06483672: Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases

Not yet recruiting
2
27
NA
Furmonertinib, AST2818, Anlotinib, No other intervention names
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Adenocarcinoma of Lung Metastatic to Brain
12/25
12/27
FORCE, NCT05379803: High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases

Recruiting
2
40
RoW
Furmonertinib, AST2818
Hunan Province Tumor Hospital
Non-Small Cell Lung Cancer
12/24
03/25
NCT05987826: Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

Not yet recruiting
2
40
NA
Furmonertinib, Furmonertinib(AST2818)
Shanghai Zhongshan Hospital, Xuhui Central Hospital, Shanghai, Shanghai Minhang Central Hospital, Shanghai Zhongshan Hospital Qingpu Branch, Ningbo No. 1 Hospital
Non-Small Cell Lung Cancer
08/24
12/25
ChiCTR2200060151: Furonertinib mesylate with Icotinib as first line treatment in locally advanced or metastatic non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutation positive: a single-arm single-center phase II study

Recruiting
2
40
 
Furmonertinib+Icotinib
Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University, Xisike-Allist Lung Cancer Target Therapy Research Foundation; Shanghai Allist Pharmaceuticals Co., Ltd.; Betta Pharmaceuticals Co., Ltd.
Lung cancer
 
 
Better Brain, NCT06728865: Evaluation of the Efficacy and Safety of Furmonertinib Combined with Bevacizumab As First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer with Brain Metastases: a Single-Arm, Open-Label, Prospective Phase II Clinical Study

Recruiting
2
70
RoW
The treatment regimen is Furmonertinib combined with Bevacizumab.
Li-kun Chen
Non-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer, Brain Metastases, Leptomeningeal Metastases, Intracranial Tumor Progression
02/28
02/28
NCT06537297: Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

Not yet recruiting
2
30
RoW
Intrathecal Pemetrexed and high-dose Furmonertinib plus bevacizumab, intrathecal pemetrexed, high-dose furmonertinib, bevacizumab
Hunan Province Tumor Hospital
Non-small Cell Lung Cancer
08/25
04/26
NCT05847764: Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Not yet recruiting
2
95
RoW
RC48+Tislelizumab+carboplatin, RC48+Furmonertinib, 1L, RC48+Furmonertinib, 2L+
Sun Yat-sen University
Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, RC48, Disitamab Vedotin
10/24
05/25
NCT06585644: A Clinical Trial of Furmonertinib Combination Therapy As Neoadjuvant Treatment in Resectable EGFR-Mutated NSCLC

Not yet recruiting
2
44
NA
Shanghai Pulmonary Hospital, Shanghai, China
Lung Cancer (NSCLC)
11/25
06/30
NCT06652048: High-dose Furmonertinib or Combined with Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

Not yet recruiting
2
60
NA
Furmonertinib 160mg QD, Furmonertinib 240mg QD, Furmonertinib 160mg QD plus Chemotherapy
Jialei Wang
Non-Small Cell Lung Cancer
12/26
12/27
ATHEM, NCT05165355: Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma

Recruiting
2
90
RoW
Furmonertinib
Tongji University
NSCLC, EGF-R Positive Non-Small Cell Lung Cancer
11/24
02/25
NCT06812871: High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Recruiting
2
30
RoW
furmonertinib, bevacizumab, pemetrexed
Sun Yat-sen University
Non-small Cell Lung Cancer Metastatic
12/25
04/26
NCT06668103: A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

Recruiting
2
54
RoW
ABSK043 in combination with Firmonertinib
Abbisko Therapeutics Co, Ltd
Non-Small Cell Lung Cancer With EGFR Mutation
12/27
06/28
ChiCTR2100053119: A multicenter, open label, single arm study: furmonertinib as neoadjuvant therapy for resectable stage IIIA EGFR mutant lung adenocarcinoma

Recruiting
2
40
 
Furmonertinib
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Hospital; Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Hospital, Shanghai Allis Pharmaceuticals Co.,Ltd.
Non-small cell lung cancer
 
 
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Recruiting
2
280
RoW
Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd.
Non-small Cell Lung Cancer
02/25
02/28
NCT06890182: Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC

Not yet recruiting
2
31
NA
Firmonertinib combined with Carboplatin/Cisplatin and Pemetrexed
Tianjin Medical University Cancer Institute and Hospital
Non-small Cell Lung Cancer
12/26
12/27
NCT06861218: Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases

Not yet recruiting
2
42
RoW
pemetrexed, vometinib
Zhejiang Cancer Hospital
Leptomeningeal Metastases
05/28
12/28
NCT05813522: Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC

Enrolling by invitation
2
30
RoW
Furmonertinib Mesilate Tablets, AST2818
First Affiliated Hospital of Zhejiang University
Non Small Cell Lung Cancer
04/25
08/25
ChiCTR2200062769: A Clinical Study of Furmonertinib Combined with Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIA EGFRm NSCLC

Not yet recruiting
2
42
 
Furmonertinib+ Pemetrexed + Carboplatin
Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, Shanghai Allist Pharmaceuticals Co, Ltd.
Non small cell lung cancer
 
 
ChiCTR2300076542: An IIT, open-label, multi-arm, prospective clinical study to investigate the efficacy and safety of toripalimab combined with furmonertinib in non-small cell lung cancer patients with EGFR sensitive mutations and PD-L1 >= 1% of first-line treatment

Not yet recruiting
2
36
 
Cohort 1: Furmonertinib 80mg orally once a day + Toripalimab 240mg intravenously every 3 weeks.Cohort 2: Induction therapy with 80mg of Furmonertinib in first 8 weeks, sequential oral administration of Furmonertinib 80mg once a day + Toripalimab 240mg intravenously every 3 weeks.
West China Hospital of Sichuan University; West China Hospital of Sichuan University, Partly funded by Shanghai Junshi Biosciences Co.,Ltd., and partly self-funded
non-small-cell lung cancer
 
 
ChiCTR2200063595: A clinical study to evaluate the efficacy and safety of Furmonertinib combined with bevacizumab or Furmonertinib monotherapy in patients with brain metastases from non-squamous non-small cell lung cancer

Recruiting
2
40
 
Furmonertinib ;Furmonertinib combined with bevacizumab
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Cancer Hospital）; The First Affiliated Hospital of University of Science and Technology of China, Shanghai Allist Pharmaceuticals Co., Ltd.
Non small cell lung cancer
 
 
ChiCTR2300071395: The efficacy and safety of Furmonertinib in advanced EGFR mutation-positive NSCLC patients with brain metastases based on real-time dynamic monitoring of peripheral blood and CSF

Not yet recruiting
2
120
 
Furmonertinib 160mg, po, qd ;Furmonertinib 80 mg, po, qd ;Furmonertinib 160 mg, po, qd ;Furmonertinib 160 mg, po, qd combined with intrathecal injection MTX or MTA
Beijing Tiantan Hospital, Capital Medical University; Beijing Tiantan Hospital, Capital Medical University, National Natural Science Foundation of China(NO.81974361); Beijing Xisike Clinical Oncology Research foundation(Y-2021AST/zd-0127)
Lung Cancer
 
 
NCT05445310: Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer

Recruiting
2
114
RoW
Furmonertinib
Peking Union Medical College Hospital
Non-small Cell Lung Cancer
07/26
07/26
ChiCTR2400084196: High-dose furmonertinib in combination with chemotherapy for the first-line treatment of treatment of EGFR mutant NSCLC with CNS metastasis : an open-label, single-arm study

Not yet recruiting
2
25
 
Furmonertinib 160mg daily + Pemetrexed (500 mg/m2) plus carboplatin (AUC 5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by pemetrexed (500 mg/m2) maintenance every 3 weeks.
Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital, self-raised
Lung cancer CNS metastases
 
 
PURPOSE Trial, ChiCTR2100053021: Precise neoadjuvant therapy for locally advanced non-small cell lung cancer: a prospective, observational, umbrella trial

Not yet recruiting
2
156
 
Almonertinib ;Furmonertinib ;Osimertinib ;Ensartinib/Savolitinib/Pralsetinib/Pyrotinib ;Camrelizumab+chemotherapy ;Chemotherapy
Shanghai Chest Hospital; Shanghai Chest Hospital, Self-raised
Locally advanced non-small cell lung cancer
 
 
160mg as first line in locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR classical mutations, ChiCTR2400086161: The efficacy and safety of furmonertinib , a prospective, single-arm, multicenter clinical study

Not yet recruiting
2
144
 
Furmonertinib 160mg, PO, QD
Peking Union Medical College Hospital; Peking Union Medical College Hospital, ALLIST
Locally advanced or metastatic non-small cell lung cancer with EGFR classical mutations
 
 
ChiCTR2400088570: A Phase II Clinical Study Evaluating the Efficacy and Safety of Adjuvant Furmonertinib for Patients With EGFR-Mutated Stage IA Non-Small Cell Lung Cancer After Non-Radical Therapy

Not yet recruiting
2
88
 
Furmonertinib; Furmonertinib
Shanghai Chest Hospital; Shanghai Chest Hospital, Self-raised
EGFR-mutant stage IA non-small cell lung cancer after non-radical treatment
 
 
NCT05079022: ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

Not yet recruiting
1/2
50
RoW
Furmonertinib, AST2818, AST5902
Peking University People's Hospital, Beijing CSCO-Allist Cancer Research Foundation, Shanghai Allist Pharmaceutical Technology Co., Ltd., Guangzhou Burning Rock Medical Examination Institute Co., Ltd.
Adenocarcinoma of Lung
03/23
09/24
NCT05821933: RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

Recruiting
1/2
106
RoW
RC108, Furmonertinib, Toripalimab
RemeGen Co., Ltd.
NSCLC
09/25
09/26
NCT05994131: IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

Recruiting
1/2
110
RoW
IN10018, BI 853520, Furmonertinib
InxMed (Shanghai) Co., Ltd.
NSCLC
07/26
07/26
FAVOUR, NCT04858958: Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation

Active, not recruiting
1
30
RoW
Furmonertinib 160mg, Furmonertinib 240mg
Allist Pharmaceuticals, Inc.
NSCLC
12/24
08/25
ChiCTR2200064008: Efficacy and Safety of Furmonertinib in Locally Advanced and Metastatic Non-Small-Cell Lung Cancer Harbouring HER2 Exon 20 Insertion: A Single-Center, Open-Label, Phase Ib Trial

Not yet recruiting
1
30
 
Furmonertinib 240mg, po, qd ;Furmonertinib 240mg, po, qd
Chinese PLA General Hospital; Chinese PLA General Hospital, Allist Pharmaceuticals, Inc.
non-small cell lung cancer (NSCLC)
 
 
NCT06868732: Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC

Not yet recruiting
1
288
NA
JSKN016, Carboplatin, Carboplatin Injection, Furmonertinib Mesylate, Furmonertinib Mesylate Tablets, Ivonescimab, Ivonescimab Injection, Docetaxel, Docetaxel injection, Tislelizumab, Tislelizumab Injection, Pembrolizumab, Pembrolizumab Injection
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Non-small Cell Lung Cancer
06/28
12/28
ChiCTR2200060897: High Dose FurmOnertinib in treatment naive advanced non-small cell lung Cancer patients Harbouring EGFR Exon 21 L858R mutation:a prospective, multicenter, single arm, open label, phase Ib study

Not yet recruiting
1
25
 
Furmonertinib 160mg Oral QD
JiangSu Cancer Hospital ; JiangSu Cancer Hospital, Shanghai Allist Pharmaceuticals Co., Ltd.
Non Small Cell lung cancer
 
 
FURMO-002, NCT05364073: Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Active, not recruiting
1
170
Europe, Canada, Japan, US, RoW
Furmonertinib, AST2818
ArriVent BioPharma, Inc.
Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, HER2 Exon 20 Mutations, EGFR Exon 20 Mutations, EGFR Uncommon Mutations, Including G719X and S768I
09/25
09/25
ChiCTR2400088658: Phase I clinical study of induction radiotherapy followed by neoadjuvant chemotherapy combined with Furmonertinib and adjuvant therapy with single-agent Furmonertinib for EGFR mutated resectable non-small cell lung cancer

Not yet recruiting
1
60
 
8Gy x Three times radiotherapy of peripheral primary focus 4Gy x Three times radiotherapy of central primary focus ; Pemetrexed 500mg/m2+ carboplatin AUC=5; D1, D22; Vometinib 80mg/ time orally, once a day, chemotherapy was started simultaneously, D1 ~ D49/56/63, until 1 week before surgery. Starting from 4 to 6 weeks after surgery, and no later than 8 weeks after surgery, continue to consolidate targeted therapy, orally once a day for 2 years
Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, Self-raised
resectable stage IIA-IIIA non-small cell lung cancer
 
 
ChiCTR2300077828: Double-Dose Versus Conventional-Dose Furmonertinib for the First-Line Treatment of EGFR-Mutated NSCLC with Malignant Pleural Effusion: An Open-Label, Randomized Controlled, Multicenter, Phase Ib Trial

Not yet recruiting
1
50
 
Furmonertinib 80mg QD; Furmonertinib 160mg QD
The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University, Shanghai Allist Pharmaceuticals Co., Ltd.
Non-small cell lung cancer
 
 
NCT06613633: Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

Completed
N/A
4000
RoW
third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)
Fudan University, Shanghai Chest Hospital, Wuhan TongJi Hospital
Third-generation TKI, NSCLC (Advanced Non-small Cell Lung Cancer)
08/24
09/24
NCT06352502: An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis

Recruiting
N/A
30
RoW
Furmonertinib, AST2818
Tang-Du Hospital
EGF-R Positive Non-Small Cell Lung Cancer, CNS Metastases
09/24
09/24
NCT06604689: AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases

Recruiting
N/A
800
RoW
third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
Fudan University
NSCLC (Advanced Non-small Cell Lung Cancer), Brain Metastasases
04/25
10/25
ChiCTR2200066546: High-dose Furmonertinib in first-line treatment of patients with EGFR classically mutated advanced NSCLC: a multicenter, open-label, single-arm, clinical study

Recruiting
N/A
15
 
Furmonertinib 160mg
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Shanghai Allist Pharmaceutical Technology Co. LTD
Non-small cell lung cancer
 
 
NCT06643000: Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis

Recruiting
N/A
60
RoW
furmonertinib, bevacizumab, pemetrexed
Henan Cancer Hospital
Non-small Cell Lung Cancer, Leptomeningeal Metastasis, EGFR Gene Mutation
03/25
05/25
NCT06926803: A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With Leptomeningeal Metastases

Active, not recruiting
N/A
500
RoW
Qiming Wang
Lung Cancer (NSCLC), Leptomeningeal Cancer
06/25
08/25
A clinical study of Furmonertinib in patients with resectable multiple primary NSCLC after one-side R0 resection, ChiCTR2300068802: A multicenter, single-arm clinical study to evaluate the efficacy and safety of Furmonertinib treatment in patients with resectable multiple primary NSCLC after one-side R0 resection

Not yet recruiting
N/A
20
 
Furmonertinib
The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University, Shanghai Allist Pharmaceuticals Co., Ltd.
Non-small cell lung cancer
 
 
ChiCTR2300072092: A single-center,real-world study to evaluate the efficacy and safety of Furmonertinib-Mesylate of 240mg/ day in the treatment of advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor gene mutation and Leptomeningeal metastasis

Recruiting
N/A
50
 
Furmonertinib oral 240mg/d
Henan Cancer Hospital; Henan Cancer Hospital, self-financing
advanced non-small cell lung cancer with epidermal growth factor receptor gene mutation and leptomeningeal metastasis
 
 
NCT06117644: The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Not yet recruiting
N/A
30
NA
Furmonertinib
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Non Small Cell Lung Cancer, EGFR Gene Mutation, Non Small Cell Lung Cancer Stage IIIA, Non-small Cell Lung Cancer Stage IV
11/25
10/26
ChiCTR2500096734: A real-world study of vormetinib in patients with EGFR mutation-positive NSCLC who relapsed after adjuvant therapy with the first generation EGFR-TKI after radical surgery

Recruiting
N/A
50
 
Furmonertinib
The Forthe Hospital of Hebei Medical University; The Forthe Hospital of Hebei Medical University, Funding provided by the researcher
EGFR Mutation-Positive NSCLC Patients with Recurrence After Adjuvant Therapy with First-Generation EGFR-TKIs Following Radical Resection
 
 
ChiCTR2400088200: A prospective, single-arm clinical study of furmonertinib combined with chemotherapy in the first-line treatment of patients with EGFR mutant locally advanced or metastatic non-small cell lung cancer

Not yet recruiting
N/A
51
 
furmonertinib combined with chemotherapy
hunan cancer hospital; hunan cancer hospital, National Natural Science Foundation of China;Hunan Provincial Health Commission;Natural Science Foundation Project of Changsha Science and Technology Bureau;Guangdong Clinical Trial Association/China Thoracic Tumour Research Collaboration Group and Guangdon;Shanghai Allist Pharmaceuticals Co., Ltd.
EGFR mutation positive locally advanced or metastatic non-small cell lung cancer
 
 

Download Options